Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long Term, Randomised, Double Blind, Placebo-controlled Study to Determine the Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Patients With Type 2 Diabetes Mellitus

NCT02465515 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT02465515
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02465515 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long Term, Randomised, Double Blind, Placebo-controlled Study to Determine the Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Patients With Type 2 Diabetes Mellitus
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Completed
Start date
July 1, 2015
Completion date
March 14, 2018
Enrollment
9,463 (actual)
Sites
607

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus